Date: January 22, 2021

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine After Care Sheet

• The After Care Sheet has been revised to indicate that the BC COVID-19 Self-Assessment Tool should be used if the vaccine recipient experiences any symptoms compatible with COVID-19 infection, including respiratory symptoms (runny nose, sore throat, shortness of breath, etc.) or any symptoms listed as vaccine side effects, with the exception of local injection site reactions. This will determine whether they need to get tested for COVID-19.

Please remove the following pages: 1-2 dated January 13, 2021
Please add the following pages: 1-2 dated January 22, 2021

Immune Globulins

Immune Globulin (Ig): GamaSTAN®

• The product name has been revised from GamaSTAN® S/D to GamaSTAN®.
• Indications for post-exposure prophylaxis of hepatitis A contacts have been revised to include the following groups for whom hepatitis A vaccine and Ig should be provided:
  o susceptible individuals with chronic liver disease
  o immunocompromised individuals who may not fully respond to the vaccine
  o may be considered for susceptible persons aged ≥ 60 years who are household or close contacts of a case of hepatitis A
• Footnote A has been added, indicating to see the Communicable Disease Control Manual, Chapter 1: Hepatitis A for information regarding hepatitis A contact management, including exposures in daycare centres and institutional settings.
• Indication for pre-exposure prophylaxis for hepatitis A has been removed. For information regarding the use of pre-exposure Ig for the purpose of travel, see the Canadian Immunization Guide: Part 5 - Passive Immunization.
• The dosage for post-exposure prophylaxis of hepatitis A contacts has been revised to 0.1 mL/kg as per the GamaSTAN® product monograph.

Please remove page numbers: 1-3 dated April 2015
Please add new page numbers: 1-3 dated January 2021

Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella or Varicella Virus

• The dose for immune globulin (Ig) for post-exposure prophylaxis for hepatitis A has been revised to 0.1 mL/kg.

Please remove page numbers: 1-2 dated January 2016
Please add new page numbers: 1-2 dated January 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated December 23, 2020, and replace with the enclosed updated Title Page and Table of Contents dated January 2021.

COVID-19 Immunization Program - Question and Answer Document for Health Care Professionals

• Question # 28 of the Q&A has been updated to indicate that in the context of limited supply, to allow for the protection of a larger number of at-risk individuals, vaccination with a COVID-19 vaccine may be delayed for 3 months following a PCR-confirmed infection, as reinfections reported to date have been rare within the first three months following infection. The updated Q&A can be found on the Immunization Clinical Resources page and the COVID-19 Vaccine – Resources for health professionals page.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division